

## AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN DIABETES ASSOCIATION CONSENSUS STATEMENT ON INPATIENT GLYCEMIC CONTROL

*Etie S. Moghissi, MD, FACP, FACE<sup>1</sup>; Mary T. Korytkowski, MD<sup>2</sup>;  
Monica DiNardo, MSN, CRNP, CDE<sup>3</sup>; Daniel Einhorn, MD, FACP, FACE<sup>4</sup>;  
Richard Hellman, MD, FACP, FACE<sup>5</sup>; Irl B. Hirsch, MD<sup>6</sup>; Silvio E. Inzucchi, MD<sup>7</sup>;  
Faramarz Ismail-Beigi, MD, PhD<sup>8</sup>; M. Sue Kirkman, MD<sup>9</sup>;  
Guillermo E. Umpierrez, MD, FACP, FACE<sup>10</sup>*

### Abbreviations:

**AACE** = American Association of Clinical Endocrinologists; **ACE** = American College of Endocrinology; **ADA** = American Diabetes Association; **AMI** = acute myocardial infarction; **BG** = blood glucose; **DIGAMI** = Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction; **ICUs** = intensive care units; **IV** = intravenous; **LOS** = length of stay; **NICE-SUGAR** = Normoglycemia in Intensive Care Evaluation—Survival Using Glucose Algorithm Regulation; **POC** = point-of-care; **RCTs** = randomized controlled trials; **SSI** = sliding scale insulin

This report is being published concurrently in 2009 in *Endocrine Practice* and *Diabetes Care* by the American Association of Clinical Endocrinologists and the American Diabetes Association.

From the <sup>1</sup>Department of Medicine, University of California Los Angeles, Los Angeles, California, <sup>2</sup>Department of Medicine, Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania, <sup>3</sup>Division of Endocrinology and Metabolism, Veterans Affairs Pittsburgh Health Center and University of Pittsburgh School of Nursing PhD Program, Pittsburgh, Pennsylvania, <sup>4</sup>Scripps Whittier Diabetes Institute, La Jolla, California, University of California San Diego School of Medicine, San Diego, California, and Diabetes and Endocrine Associates, La Jolla, California, <sup>5</sup>Department of Medicine, University of Missouri-Kansas City School of Medicine and Hellman and Rosen Endocrine Associates, North Kansas City, Missouri, <sup>6</sup>Department of Medicine, University of Washington School of Medicine, Seattle, Washington, <sup>7</sup>Department of Medicine, Section of Endocrinology, Yale University School of Medicine and the Yale Diabetes Center, Yale-New Haven Hospital, New Haven, Connecticut, <sup>8</sup>Department of Medicine, Physiology and Biophysics, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, Cleveland, Ohio, <sup>9</sup>Clinical Affairs, American Diabetes Association, Alexandria, Virginia, and <sup>10</sup>Department of Medicine/Endocrinology, Emory University, Atlanta, Georgia.

Address correspondence and reprint requests to Dr. Etie S. Moghissi, 4644 Lincoln Boulevard, Suite 409, Marina del Rey, CA 90292.

© 2009 by the American Association of Clinical Endocrinologists and the American Diabetes Association.

DOI: 10.4158/EP09102.RA

### INTRODUCTION

People with diabetes are more likely to be hospitalized and to have longer durations of hospital stay than those without diabetes. A recent survey estimated that 22% of all hospital inpatient days were incurred by people with diabetes and that hospital inpatient care accounted for half of the \$174 billion total US medical expenditures for this disease (1). These findings are due, in part, to the continued expansion of the worldwide epidemic of type 2 diabetes. In the United States alone, there are approximately 1.6 million new cases of diabetes each year, with an overall prevalence of 23.6 million people (7.8% of the population, with one-fourth of the cases remaining undiagnosed). An additional 57 million American adults are at high risk for type 2 diabetes (2). Although the costs of illness-related stress hyperglycemia are not known, they are likely to be considerable in light of the poor prognosis of such patients (3-6).

There is substantial observational evidence linking hyperglycemia in hospitalized patients (with or without diabetes) to poor outcomes. Cohort studies as well as a few early randomized controlled trials (RCTs) suggested that intensive treatment of hyperglycemia improved hospital outcomes (5-8). In 2004, this evidence led the American College of Endocrinology (ACE) and the American Association of Clinical Endocrinologists (AACE), in collaboration with the American Diabetes Association (ADA) and other medical organizations, to develop recommendations for treatment of inpatient hyperglycemia (9). In 2005, the ADA added recommendations for treatment of hyperglycemia in the hospital to its annual Standards of Medical Care (10). Recommendations from ACE and ADA generally endorsed tight glycemic control in critical care units. For patients in general medical and surgical units, where RCT evidence regarding treatment targets was lacking, glycemic goals similar to those advised for outpatients were advocated (9,10). In 2006, ACE and ADA partnered on a joint "Call to Action" for inpatient glycemic control,

addressing a number of systematic implementation barriers in hospitals (11). These efforts contributed to a growing national movement viewing the management of inpatient hyperglycemia as a quality-of-care measure.

Although hyperglycemia is associated with adverse patient outcomes, intervention to normalize glycemia has yielded inconsistent results. Indeed, recent trials in critically ill patients have failed to show a significant improvement in mortality with intensive glyceemic control (12,13) or have even shown increased mortality risk (14). Moreover, these recent RCTs have highlighted the risk of severe hypoglycemia resulting from such efforts (12-17). These outcomes have contributed to confusion regarding specific glyceemic targets and the means for achieving them in both critically ill and noncritically ill patients.

Recognizing the importance of glyceemic control across the continuum of care, AACE and ADA joined forces to develop this updated consensus statement on inpatient glyceemic management. The central goals were to identify *reasonable, achievable, and safe* glyceemic targets and to describe the protocols, procedures, and system improvements needed to facilitate their implementation. This document is addressed to health care professionals, supporting staff, hospital administrators, and other stakeholders focused on improved management of hyperglycemia in inpatient settings. Consensus panel members extensively reviewed the most current literature and considered the following questions:

1. Does improving glyceemic control improve clinical outcomes for inpatients with hyperglycemia?
2. What glyceemic targets can be recommended in different patient populations?
3. What treatment options are available for achieving optimal glyceemic targets safely and effectively in specific clinical situations?
4. Does inpatient management of hyperglycemia represent a safety concern?
5. What systems need to be in place to achieve these recommendations?
6. Is treatment of inpatient hyperglycemia cost-effective?
7. What are the optimal strategies for transition to outpatient care?
8. What are areas for future research?

**QUESTION 1: Does improving glyceemic control improve clinical outcomes for inpatients with hyperglycemia?**

Hyperglycemia in hospitalized patients, irrespective of its cause, is unequivocally associated with adverse outcomes (5,6,18-25). Hyperglycemia occurs in patients with known or undiagnosed diabetes, or it occurs during acute illness in those with previously normal glucose tolerance (termed “stress hyperglycemia”) (8,26).

Intervention directed at reducing blood glucose (BG) levels has resulted in improved outcomes in some, but not all, studies (5,18-25). Several recent clinical trials in critically ill patients have reported no reduction in mortality from intensive treatment targeting near-euglycemia versus conventional management targeting BG <180 mg/dL (<10.0 mmol/L). Of considerable concern are reports of harm, with higher rates of severe hypoglycemia and even increased mortality (14) resulting from intensive glyceemic control (12-14,16,27,28). This variability in results may be attributable to several factors, including differences in intravenous (IV) insulin treatment protocols and their implementation, glyceemic targets, patient populations, methods for glucose monitoring, and insulin adjustment (12,29).

The following section focuses primarily on results of recent studies with RCT design that investigated patient outcomes with protocols targeting near-normalization of BG levels. Readers are referred to a previous ACE position statement (9), an ACE/ADA consensus statement (11), and a technical review (8) for details related to earlier studies supporting inpatient glyceemic management.

**Data Derived From Surgical and Medical Intensive Care Units**

Observational studies have documented that hyperglycemia after cardiothoracic surgical procedures is associated with higher rates (approximately 2-fold) of wound infection (20,30). Interventions to reduce hyperglycemia in this setting with IV insulin therapy decrease infection rates (19,21,31) and cardiac-related mortality (5,32), in comparison with historical control subjects.

The results of several RCTs conducted in critically ill patients in medical and surgical intensive care units (ICUs) are summarized in Table 1 (5,13,14,16,27,28,33-36). Intensive insulin therapy targeting arterial glucose levels of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) in a primarily surgical ICU patient population resulted in a significant decrease in morbidity and mortality (5). However, implementation of the identical protocol in 1,200 medical ICU patients by the same investigators in the same institution diminished morbidity but failed to reduce mortality. A 6-fold increase in severe hypoglycemic events (BG <40 mg/dL [2.2 mmol/L]) was observed in the intensively treated group (18.7% versus 3.1%), and hypoglycemia was identified as an independent risk factor for mortality (16).

The Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) study reported no decrease in mortality and higher rates of severe hypoglycemia with intensive insulin therapy in patients with severe sepsis (17% versus 4.1%;  $P<.001$ ) (13). Hypoglycemia—BG <40 mg/dL (<2.2 mmol/L)—was identified as an independent risk factor for mortality (relative risk, 2.2 at 28 days; 95% confidence interval, 1.6 to 3.0) (Dr. Frank Brunkhorst, personal communication, 2009). Similarly, intensive glyceemic control in a mixed medical and surgi-

**Table 1**  
**Summary Data of Selected Randomized Controlled Trials of Intensive Insulin Therapy in Critically Ill Patients (>200 Randomized Patients)<sup>a</sup>**

Trial	N	Setting	Blood glucose target, mg/dL (mmol/L)		Blood glucose achieved, mg/dL (mmol/L)		Primary outcome	End point rate		RRR <sup>c</sup>	ARR <sup>c</sup>	Odds ratio <sup>c</sup> (95% CI)
			Intensive	Conventional	Intensive	Conventional		Intensive	Conventional			
DIGAMI (33), 1995	620	CCU (AMI)	126-196 (7-10.9)	Usual care	173 (9.6)	211 (11.7)	1-year mortality	18.6%	26.1%	29% <sup>d</sup>	7.5%	NR
Van den Berghe et al (5), 2001	1,548	SICU	80-110 (4.4-6.1)	180-200 (10-11)	103 (5.7)	153 (8.5)	ICU mortality	4.6%	8.0%	42%	3.4%	0.58 <sup>d</sup> (0.38-0.78)
DIGAMI 2 (34), 2005	1,253	CCU (AMI)	126-180 (7-10) (groups 1 & 2)	Usual care (group 3)	164 (9.1)	180 (10)	2-year mortality	Group 1, 23.4%; group 2, 21.2%	Group 3, 17.9%	... <sup>e</sup>	... <sup>e</sup>	NR
Van den Berghe et al (16), 2006	1,200	MICU	80-110 (4.4-6.1)	180-200 (10-11)	111 (6.2)	153 (8.5)	Hospital mortality	37.3%	40.0%	7.0%	2.7%	0.94 <sup>e</sup> (0.84-1.06)
HI-5 (35), 2006	240	CCU (AMI) (GIK)	72-180 (4-10)	Usual care (<288 (<16))	149 (8.3)	162 (9)	6-month mortality	7.9%	6.1%	-30% <sup>e</sup>	-1.8% <sup>e</sup>	NR
GluControl <sup>f</sup> (27), 2007	1,101	ICU	80-110 (4.4-6.1)	140-180 (7.8-10)	118 (6.5)	144 (8)	ICU mortality	16.7%	15.2%	-10%	-1.5%	1.10 <sup>e</sup> (0.84-1.44)
Gandhi et al (36), 2007	399	Operating room	80-110 (4.4-6.1)	<200 (<11)	114 (6.3)	157 (8.7)	Composite <sup>g</sup>	44%	46%	4.3%	2%	1.0 <sup>e</sup> (0.8-1.2)
VISEP (13), 2008	537 <sup>h</sup>	ICU	80-110 (4.4-6.1)	180-200 (10-11)	112 (6.2)	151 (8.4)	28-day mortality	24.7%	26.0%	5.0%	1.3%	0.89 <sup>ai</sup> (0.58-1.38)
De La Rosa et al <sup>f</sup> (28), 2008	504	SICU MICU	80-110 (4.4-6.1)	180-200 (10-11)	117 (6.5)	148 (8.2)	28-day mortality	36.6%	32.4%	-13% <sup>e</sup>	-4.2% <sup>e</sup>	NR
NICE-SUGAR (14), 2009	6,104	ICU	81-108 (4.5-6)	≤180 (≤10)	115 (6.4)	145 (8.0)	3-month mortality	27.5%	24.9%	-10.6%	-2.6%	1.14 <sup>d</sup> (1.02-1.28)

<sup>a</sup> AMI = acute myocardial infarction; ARR = absolute risk reduction; CCU = coronary care unit; CI = confidence interval; GIK = glucose-insulin-potassium; ICU = intensive care units (mixed); MICU = medical intensive care unit(s); NR = not reported; RRR = relative risk reduction; SICU = surgical intensive care unit.

<sup>b</sup> Mean morning blood glucose concentrations (except for GluControl, which reported mean overall blood glucose concentrations).

<sup>c</sup> Intensive group versus conventional group.

<sup>d</sup>  $P < 0.05$ .

<sup>e</sup> Not significant ( $P > 0.05$ ).

<sup>f</sup> Presented as abstract only.

<sup>g</sup> Composite of death, sternal infection, prolonged ventilation, cardiac arrhythmias, stroke, and renal failure at 30 days.

<sup>h</sup> Only patients with sepsis.

<sup>i</sup> Personal communications, Dr. Frank Brunkhorst.

cal ICU resulted in no decrease in morbidity or mortality, while increasing the rate of hypoglycemia 5-fold (28).

The largest study to date, Normoglycemia in Intensive Care Evaluation—Survival Using Glucose Algorithm Regulation (NICE-SUGAR), a multicenter, multinational RCT, tested the effect of tight glycemic control on outcomes among 6,104 critically ill participants, the majority of whom (>95%) required mechanical ventilation (14). The 90-day mortality was significantly higher in the intensively treated versus the conventionally treated group (78 more deaths; 27.5% versus 24.9%;  $P = .02$ ) in both surgical and medical patients. Mortality from cardiovascular causes was more common in the intensively treated group (76 more deaths; 41.6% versus 35.8%;  $P = .02$ ). Severe hypoglycemia was also more common in the intensively treated group (6.8% versus 0.5%;  $P < .001$ ).

A recent meta-analysis of RCTs reported comparisons between intensive insulin therapy with glycemic targets of 72 to 126 mg/dL (4.0 to 7.0 mmol/L) (commonly, 80 to 110 mg/dL [4.4 to 6.1 mmol/L]) and less intensive therapy with targets of <150 to 220 mg/dL (<8.3 to 12.2 mmol/L) (commonly, 180 to 200 mg/dL [10.0 to 11.1 mmol/L]). Among 8,432 critically ill patients, there was no significant difference in mortality between intensive therapy and control groups (21.6% versus 23.3%, respectively) (12). A decrease in septicemia and a 5-fold increase in hypoglycemia (13.7% versus 2.5%) were observed. In a second meta-analysis (17) including 13,567 critically ill patients, a favorable effect of intensive therapy on mortality was noted only in surgical ICU patients (relative risk, 0.63; confidence interval, 0.44 to 0.91). There was a 6-fold increase in the rate of occurrence of hypoglycemia with use of intensive therapy in all ICU patients (17).

The higher rates of severe hypoglycemia associated with intensive insulin therapy (12-14,16,27,28) raise the possibility that serious adverse events in the subgroup of patients experiencing hypoglycemia offset, at least in part, any benefit derived from strict glycemic control in the much larger subgroup of patients without hypoglycemic events (13,16). Hypoglycemic events, however, have been infrequently linked to mortality; this finding suggests that severe hypoglycemia may be a marker of more serious underlying disease (13,14,16).

#### **Data Derived From Patients With Acute Myocardial Infarction**

Although hyperglycemia is associated with adverse outcomes after acute myocardial infarction (AMI) (37-41), reduction of glycemia per se, and not necessarily the use of insulin, is associated with improved outcomes (7). It remains unclear, however, whether hyperglycemia is a marker of underlying health status or is a mediator of complications after AMI. Non-iatrogenic hypoglycemia has also been associated with adverse outcomes and is a predictor of higher mortality (7,42,43).

Several studies have attempted to reproduce the favorable outcomes observed with early implementation of insulin therapy reported in the first Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) trial (33). DIGAMI 2, a multicenter RCT of 1,253 patients with AMI and diabetes, failed to show a decrease in mortality with such intervention (34). The Hyperglycemia Intensive Insulin Infusion in Infarction (HI-5) study randomly assigned patients with AMI to 24-hour infusions of insulin plus glucose for 24 hours (BG goal <180 mg/dL [ $<10.0$  mmol/L]) or usual care. There were no significant differences in mortality, although there was a decreased incidence of congestive heart failure and reinfarction at 3 months in the intensively treated group (35). The very large Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation—Estudios Cardiológicos Latin America (CREATE-ECLA), with 20,201 patients, tested the efficacy of glucose-insulin-potassium infusion in post-AMI patients and found no decrease in mortality (44). A failure to achieve a prespecified glycemic target with intensive therapy that differed from those in the control group may have contributed to these negative results (34,44).

#### **Data Derived From Other Critically Ill Patients**

Several retrospective studies have examined the relationship between glycemia and clinical outcomes in patients with extensive burns, body trauma, or traumatic brain injury or those who have undergone surgical treatment for cerebral aneurysms (45-53). In patients with subarachnoid hemorrhage, hyperglycemia was associated with impaired cognition and deficits in gross neurologic function at 3 months (52). Patients without diabetes who had severe blunt injury and hyperglycemia (BG >200 mg/dL [11.1 mmol/L]) were found to have a 2.2-fold higher rate of mortality than those with admission glucose of less than 200 mg/dL (11.1 mmol/L) (54). Similar findings have been reported by some investigators (55,56) but not others (57,58). In an RCT of tight glycemic control in 97 patients with severe traumatic brain injury (59), no significant differences were noted in infections, 6-month mortality, or neurologic outcomes. The rate of occurrence of hypoglycemia was 2-fold higher with use of intensive insulin therapy.

#### **Data Derived From Patients Undergoing Transplantation**

Diabetes in patients after transplant procedures shares many similarities with type 2 diabetes and is strongly associated with cardiovascular disease and cardiac death (60). Fuji et al (61) examined the effects of hyperglycemia during neutropenic periods in 112 patients undergoing stem cell transplantation. Hyperglycemia was associated with risk of organ failure, grade II to IV acute graft-versus-host disease, and non-relapse-related mortality, but not with

infection or fever. A similar study in 382 patients reported that in those patients not treated with glucocorticoids during neutropenia, each 10 mg/dL (0.6 mmol/L) increase in BG was associated with a 1.15-fold increase in the odds ratio for bacteremia (62). Hammer et al (63) analyzed BG levels among 1,175 adult patients receiving allogeneic hematopoietic cell transplants. Hyperglycemia, hypoglycemia, and glycemic variability all correlated with non-relapse-related mortality within 200 days after transplantation.

#### **Data Derived From Studies on Intraoperative Glycemic Management**

In a double-blind, placebo-controlled RCT involving 82 adults, intraoperative glucose-insulin-potassium infusion during a coronary artery bypass grafting procedure did not reduce myocardial damage, mortality, or length of stay (LOS) (64). In a study of 399 patients undergoing cardiac surgical procedures, intensive insulin therapy (target BG, 80 to 100 mg/dL [4.4 to 5.6 mmol/L]) intraoperatively resulted in no difference in patient outcomes; postoperatively, however, both groups were treated to similar glycemic targets (36).

#### **Data Derived From Pediatric ICUs**

Although outside the scope of this consensus statement, it is worth noting that hyperglycemia (without diabetes) is also common among pediatric patients with critical illness (65-70), and it correlates with mortality (70). An international, multicenter RCT, which tested the effect of intensive glycemic control in very-low-birth-weight neonates, found higher rates of severe hypoglycemia and no significant difference in mortality or morbidity (71). In contrast, another randomized trial conducted among 700 critically ill infants (n = 317) and children (n = 383) reported decreases in mortality, inflammatory markers, and LOS with use of intensive insulin therapy, despite a greater frequency of severe hypoglycemia (25% versus 5%) (72).

#### **Hyperglycemia in Hospitalized Medical and Surgical Patients in Non-ICU Settings**

No RCTs have examined the effect of intensive glycemic control on outcomes in hospitalized patients outside ICU settings. Several observational studies, however, point to a strong association between hyperglycemia and poor clinical outcomes, including prolonged hospital stay, infection, disability after discharge from the hospital, and death (4,7,35,73-81).

Several studies have found glucose variability to be an independent predictor of mortality in critically ill patients (63,66,82). Whether intervention to control glycemic variability, per se, improves outcomes is not known (83).

#### **Summary of the Clinical Trials Reviewed for Question 1**

Overall, although a very tight glucose target (80 to 110 mg/dL [4.4 to 6.1 mmol/L]) was beneficial in a predomi-

nantly surgical ICU population (5), this target has been difficult to achieve in subsequent studies, including the recently published NICE-SUGAR study (14), without increasing the risk for severe hypoglycemia (12,13,16,27,28). In addition, there has been no consistent reduction in mortality with intensive control of glycemia (12,17), and increased mortality was observed in the largest published study to date (14). The reasons for this inconsistency are not entirely clear. The positive results reported in the initial studies may have been attributable to differences in measurement and reporting of BG values, selection of participants, glycemic variability, or nutritional support (12,17,84). Nevertheless, recent attempts to achieve tight glycemic control either have not reduced or have actually increased mortality in multicenter trials and clearly led to higher rates of hypoglycemia (13,14,16).

Despite the inconsistencies, it would be a serious error to conclude that judicious control of glycemia in critically ill patients, and in non-ICU patients in general, is not warranted. First, on the basis of a large number of studies in a variety of inpatient settings, uncontrolled hyperglycemia clearly is associated with poor outcomes. Second, although severe hypoglycemic events are observed in an unacceptably high number of patients receiving intensive insulin therapy with protocols targeting a BG of 80 to 110 mg/dL (4.4 to 6.1 mmol/L) (12), this risk can likely be minimized with relaxation of targets, improvement and standardization of protocols, and their careful implementation. Third, perhaps major beneficial effects on outcomes can be derived from a higher target range of glucose than 80 to 110 mg/dL in comparison with uncontrolled hyperglycemia.

Finally, until further information becomes available, it is prudent to continue to emphasize the importance of glycemic control in hospitalized patients with critical and noncritical illness while aiming at targets that are less stringent than 80 to 110 mg/dL (4.4 to 6.1 mmol/L), a topic that is discussed in detail subsequently.

#### **QUESTION 2: What glycemic targets can be recommended in different patient populations?**

The management of hyperglycemia in the hospital presents unique challenges that stem from variations in a patient's nutritional status and level of consciousness, the practical limitations of intermittent glycemic monitoring, and the ultimate importance of patient safety. Accordingly, reasonable glucose targets in the hospital setting are modestly higher than may be routinely advised for patients with diabetes in the outpatient setting (85,86).

#### **Definition of Glucose Abnormalities**

In this report, hyperglycemia is defined as any BG value >140 mg/dL (>7.8 mmol/L). Levels that are significantly and persistently above this level may necessitate treatment in hospitalized patients. In patients without a

previous diagnosis of diabetes, elevated BG concentrations may be due to stress hyperglycemia, a condition that can be established by a review of prior medical records or measurement of hemoglobin A1c. Hemoglobin A1c values of >6.5% to 7.0% suggest that diabetes preceded hospitalization (87).

Hypoglycemia is defined as any BG level <70 mg/dL (<3.9 mmol/L) (88). This is the standard definition in outpatients and correlates with the initial threshold for the release of counterregulatory hormones (89). Severe hypoglycemia in hospitalized patients has been defined by many clinicians as <40 mg/dL (<2.2 mmol/L), although this value is lower than the approximate 50 mg/dL (2.8 mmol/L) level at which cognitive impairment begins in normal persons (89-91). As with hyperglycemia, hypoglycemia among inpatients is also associated with adverse short-term and long-term outcomes. Early recognition and treatment of mild to moderate hypoglycemia (40 and 69 mg/dL [2.2 and 3.8 mmol/L], respectively) can prevent deterioration to a more severe episode with potential adverse sequelae (91,92).

#### **Treatment of Hyperglycemia in Critically Ill Patients**

On the basis of the available evidence, insulin infusion should be used to control hyperglycemia in the majority of critically ill patients in the ICU setting, with a starting threshold of no higher than 180 mg/dL (10.0 mmol/L). Once IV insulin therapy has been initiated, the glucose level should be maintained between 140 and 180 mg/dL (7.8 and 10.0 mmol/L), and greater benefit may be realized at the lower end of this range. Although strong evidence is lacking, somewhat lower glucose targets may be appropriate in selected patients. Targets less than 110 mg/dL (6.1 mmol/L), however, are not recommended. Use of insulin infusion protocols with demonstrated safety and efficacy, resulting in low rates of occurrence of hypoglycemia, is highly recommended.

#### **Treatment of Hyperglycemia in Noncritically Ill Patients**

With no prospective, RCT data for establishing specific guidelines in noncritically ill patients, our recommendations are based on clinical experience and judgment. For the majority of noncritically ill patients treated with insulin, premeal glucose targets should generally be <140 mg/dL (<7.8 mmol/L) in conjunction with random BG values <180 mg/dL (<10.0 mmol/L), as long as these targets can be safely achieved. For avoidance of hypoglycemia, consideration should be given to reassessing the insulin regimen if BG levels decline below 100 mg/dL (5.6 mmol/L). Modification of the regimen is necessary when BG values are <70 mg/dL (<3.9 mmol/L), unless the event is easily explained by other factors (such as a missed meal).

Occasional clinically stable patients with a prior history of successful tight glycemic control in the outpatient setting may be maintained with a glucose range below

the aforementioned cut points. In contrast, higher glucose ranges may be acceptable in terminally ill patients or in patients with severe comorbidities, as well as in those in patient-care settings where frequent glucose monitoring or close nursing supervision is not feasible.

We emphasize that clinical judgment in combination with ongoing assessment of the patient's clinical status, including changes in the trajectory of glucose measures, the severity of illness, the nutritional status, or the concurrent use of medications that might affect glucose levels (for example, corticosteroids or octreotide), must be incorporated into the day-to-day decisions regarding insulin dosing (93,94).

#### **Inpatient Glucose Metrics**

Hospitals attempting to improve the quality of their glycemic control and clinical investigators who analyze glycemic management require standardized glucose measures for assessment of baseline performance and the effect of any intervention (11). Several methods have been proposed for determining the adequacy of glycemic control across a hospital or unit. A recent study indicated that a simple measure of mean BG (39) provides information similar to that from more complex metrics (hyperglycemic index, time-averaged glucose) (14,48). The "patient-day" unit of measure is another proposed metric of hospital glucose data, especially when there is substantial variability in the duration of hospital stay (95). The patient-day metric may yield a more accurate assessment of the frequency of hypoglycemia and severe hyperglycemic events, providing an approach for obtaining measures of performance for clinical investigation (95).

The absolute definition of high-quality BG control has not been determined. Of course, one should aim for the highest percentage of patients within a prespecified BG target range. The opposite holds true for hypoglycemia. What is reasonable for a hospital to achieve and with what consistency have not been studied, and information regarding best practices in this area is needed.

**QUESTION 3: What treatment options are available for achieving optimal glycemic targets safely and effectively in specific clinical situations?**

In the hospital setting, insulin therapy is the preferred method for achieving glycemic control in most clinical situations (8). In the ICU, IV infusion is the preferred route of insulin administration. Outside of critical care units, subcutaneous administration of insulin is used much more frequently. Orally administered agents have a limited role in the inpatient setting.

#### **Intravenous Insulin Infusions**

In the critical care setting, continuous IV insulin infusion has been shown to be the most effective method for achieving specific glycemic targets (8). Because of the

very short half-life of circulating insulin, IV delivery allows rapid dosing adjustments to address alterations in the status of patients.

IV insulin therapy is ideally administered by means of validated written or computerized protocols that allow for predefined adjustments in the insulin infusion rate based on glycemic fluctuations and insulin dose. An extensive review of the merits and deficiencies of published protocols is beyond the intent of this statement, and readers are referred to several available reports and reviews (96-101). Continued education of staff in conjunction with periodic ongoing review of patient data is critical for successful implementation of any insulin protocol (97-101).

Patients who receive IV insulin infusions will usually require transition to subcutaneously administered insulin when they begin eating regular meals or are transferred to lower intensity care. Typically, a percentage (usually 75% to 80%) of the total daily IV infusion dose is proportionately divided into basal and prandial components (see subsequent material). Importantly, subcutaneously administered insulin must be given 1 to 4 hours before discontinuation of IV insulin therapy in order to prevent hyperglycemia (102). Despite these recommendations, a safe and effective transition regimen has not been substantiated.

#### **Subcutaneously Administered Insulin**

Scheduled subcutaneous administration of insulin is the preferred method for achieving and maintaining glucose control in non-ICU patients with diabetes or stress hyperglycemia. The recommended components of inpatient subcutaneous insulin regimens are a basal, a nutritional, and a supplemental (correction) element (8,103). Each component can be met by one of several available insulin products, depending on the particular hospital situation. Readers are referred to several recent publications and reviews that describe currently available insulin preparations and protocols (101-106).

A topic that deserves particular attention is the persistent overuse of what has been branded as sliding scale insulin (SSI) for management of hyperglycemia. The term "correction insulin," which refers to the use of additional short- or rapid-acting insulin in conjunction with scheduled insulin doses to treat BG levels above desired targets, is preferred (8). Prolonged therapy with SSI as the sole regimen is ineffective in the majority of patients (and potentially dangerous in those with type 1 diabetes) (106-112).

#### **Noninsulin Agents**

Noninsulin agents are inappropriate in most hospitalized patients. Continued use of such agents may be appropriate in selected stable patients who are expected to consume meals at regular intervals. Caution must be exercised with use of metformin because of the potential development of a contraindication during the hospitalization, such as renal insufficiency, unstable hemodynamic status, or need for imaging studies with radiocontrast dye (8,113).

Injectable noninsulin therapies such as exenatide and pramlintide have limitations similar to those with orally administered agents in the hospital setting.

#### **Specific Clinical Situations**

##### ***Patients Using an Insulin Pump***

Patients who use continuous subcutaneous insulin infusion (pump) therapy in the outpatient setting can be candidates for diabetes self-management in the hospital, provided they have the mental and physical capacity to do so (8,103,114,115). Of importance, nursing personnel must document basal rates and bolus doses on a regular basis (at least daily). The availability of hospital personnel with expertise in continuous subcutaneous insulin infusion therapy is essential (115).

##### ***Patients Receiving Enteral Nutrition***

Hyperglycemia is a common side effect of inpatient enteral nutrition therapy (116,117). A recent study, in which a combination of basal insulin and correction insulin was used, achieved a mean glucose value of 160 mg/dL (8.9 mmol/L). Similar results were achieved in the group randomized to receive SSI only; however, 48% of patients required the addition of intermediate-acting insulin to achieve glycemic targets (109).

##### ***Patients Receiving Parenteral Nutrition***

The high glucose load in standard parenteral nutrition frequently results in hyperglycemia, which is associated with a higher incidence of complications and mortality in critically ill patients in the ICU (118). Insulin therapy is highly recommended, with glucose targets as defined previously on the basis of the severity of illness.

##### ***Patients Receiving Glucocorticoid Therapy***

Hyperglycemia is a common complication of corticosteroid therapy (93). Several approaches have been proposed for treatment of this condition, but no published protocols or studies have investigated the efficacy of these approaches. A reasonable approach is to institute glucose monitoring for at least 48 hours in all patients receiving high-dose glucocorticoid therapy and to initiate insulin therapy as appropriate (94). In patients who are already being treated for hyperglycemia, early adjustment of insulin doses is recommended (119). Importantly, during corticosteroid tapers, insulin dosing should be proactively adjusted to avoid hypoglycemia.

#### **QUESTION 4: Does inpatient management of hyperglycemia represent a safety concern?**

Overtreatment and undertreatment of hyperglycemia represent major safety issues in hospitalized patients with and without diabetes (90,120,121). Fear of hypoglycemia, clinical inertia, and medical errors are major barriers to achieving optimal blood glucose control (90,122-131).

In most clinical situations, safe and reasonable glycemic control can be achieved with appropriate use of insulin, adjusted according to results of bedside glucose monitoring (102,106,109).

Clinical situations that increase the risk for hypoglycemia and hyperglycemia in the hospital include the following:

1. Changes in caloric or carbohydrate intake (“nothing by mouth” status, enteral nutrition, or parenteral nutrition) (94,128)
2. Change in clinical status or medications (for example, corticosteroids or vasopressors) (93,98)
3. Failure of the clinician to make adjustments to glycemic therapy based on daily BG patterns (102,128)
4. Prolonged use of SSI as monotherapy (107,108)
5. Poor coordination of BG testing and administration of insulin with meals (121,129)
6. Poor communication during times of patient transfer to different care teams (120,121)
7. Use of long-acting sulfonylureas in elderly patients and those with kidney or liver insufficiency
8. Errors in order writing and transcription (102,120)

Hypoglycemia is a major safety concern with use of insulin and insulin secretagogues. Hypoglycemia can occur spontaneously in patients with sepsis (130) or in patients who receive certain medications, including quinolone antibiotics and  $\beta$ -adrenergic agonists. Although not all hypoglycemic episodes are avoidable, the use of nurse-driven hypoglycemia treatment protocols that prompt early therapy for any BG levels  $<70$  mg/dL ( $<3.9$  mmol/L) can prevent deterioration of potentially mild events—for example, BG values of 60 to 69 mg/dL (3.3 to 3.8 mmol/L)—to more severe events—for example, BG concentrations  $<40$  mg/dL ( $<2.2$  mmol/L) (90-92,98,131). Particular attention is required in high-risk patients, including those with malnutrition; advanced age; a history of severe hypoglycemia (88,132); or autonomic, kidney, liver, or cardiac failure.

Clinical inertia can be defined as not adjusting glycemic therapy in response to persistently abnormal results on BG determination (123). Often, there is a lack of ownership for diabetes management, particularly in hospitalized patients admitted with a primary diagnosis other than diabetes (128). This inaction may be due in part to insufficient knowledge or confidence in diabetes management (123,133). Improvements in care can be achieved by ongoing education and training (134,135).

#### Insulin Errors

Insulin has consistently been designated as a high-alert medication because of the risk of harm that can accompany errors in prescribing, transcribing, or dosing (136). The true frequency of such errors is unknown because the available data sources depend on voluntary reporting of errors (102,137) and mechanisms for real-time root-cause analysis are not available in most hospitals.

#### Blood Glucose Monitoring

Bedside BG monitoring with use of point-of-care (POC) glucose meters is performed before meals and at bedtime in most inpatients who are eating usual meals. It is important to avoid routine use of correction insulin at bedtime. In patients who are receiving continuous enteral or parenteral nutrition, glucose monitoring is optimally performed every 4 to 6 hours. In patients who are receiving cycled enteral nutrition or parenteral nutrition, the schedule for glucose monitoring can be individualized but should be frequent enough to detect hyperglycemia during feedings and the risk of hypoglycemia when feedings are interrupted (109,112). More frequent BG testing, ranging from every 30 minutes to every 2 hours, is required for patients receiving IV insulin infusions.

#### Glucose Meters

Safe and rational glycemic management relies on the accuracy of BG measurements performed with use of POC glucose meters, which have several important limitations. Although the US Food and Drug Administration allows a  $\pm 20\%$  error for glucose meters, questions have been raised about the appropriateness of this criterion (138). Glucose measurements differ significantly between plasma and whole blood, terms that are often used interchangeably and can lead to misinterpretation. Most commercially available capillary glucose meters introduce a correction factor of approximately 1.12 to report a “plasma adjusted” value (139).

Significant discrepancies among capillary, venous, and arterial plasma samples have been observed in patients with low or high hemoglobin concentrations, hypoperfusion, or the presence of interfering substances (139,140). Analytical variability has been described with several POC glucose meters (141). Any glucose result that does not correlate with the patient’s clinical status should be confirmed through conventional laboratory sampling of plasma glucose.

Although laboratory measurement of plasma glucose has less variability and interference, multiple daily phlebotomies are not practical. Moreover, the use of indwelling lines as the sampling source poses risks for infection. Studies performed with use of continuous interstitial glucose monitoring systems in the critical care setting (142,143) currently are limited by the lack of reliability of BG measurements in the hypoglycemic range as well as by cost.

#### QUESTION 5: What systems need to be in place to achieve these recommendations?

The complexity of inpatient glycemic management necessitates a systems approach that facilitates safe practices and reduces the risk for errors (120,121). Systems that facilitate the appropriate use of scheduled insulin therapy, with institutional support for inpatient personnel who are knowledgeable in glycemic management, are essential for



achieving safe and reasonable levels of glycemic control in hospitalized patients. Readers are referred to the 2006 ACE/ADA consensus statement, which outlines the systems that must be in place to promote effective glycemic management in the hospital (11). Some of these recommendations are reviewed briefly in the following paragraphs.

The success of any glycemic management program depends on the ability to obtain financial support from hospital administrators, who should be made aware of the potential for cost savings with reductions in morbidity, durations of hospital stay, and need for readmission. This support is necessary for covering the costs of staff education, equipment, and personnel to oversee an inpatient diabetes management program (144).

The creation of a multidisciplinary steering committee guided by local diabetes experts can establish reasonable and achievable glycemic management goals with use of protocols and order sets (90). Preprinted order sets or computerized ordering systems with adequate technical support are useful tools for facilitating appropriate glycemic therapy (8,11,145). These tools can advance orders that contain contingencies that promote patient safety, such as withholding prandial insulin if a patient will not eat (102). Protocols need to be reviewed periodically and revised in accordance with available evidence.

Inpatient providers often have insufficient knowledge about the many aspects of inpatient diabetes care (133). Thus, education of personnel is essential, especially early during the implementation phase (101,127). Formal communication among various disciplines and services helps to garner support from hospital personnel for new practices and protocols, as well as providing a venue for identifying concerns.

Many hospitals are challenged by poor coordination of meal delivery and prandial insulin administration (130), as well as variability in the carbohydrate content of meals (94). Ensuring appropriate administration of insulin with respect to meals despite variations in food delivery necessitates coordination between dietary and nursing services (122). A systems approach can also promote the coordination of glucose monitoring, insulin administration, and meal delivery, particularly during change of shifts and times of patient transfer (121,122).

Electronic health records and computerized physician order entry systems have the potential to improve the sharing of information, including POC glucose results and associated medication administration—which can contribute to the reduction of medical errors. These systems can also provide access to algorithms, protocols, and decision support tools that can help guide therapy (146,147).

#### **QUESTION 6: Is treatment of inpatient hyperglycemia cost-effective?**

A program of inpatient glycemic control with prespecified glycemic targets will have associated costs attributable

to an increase in time needed from physicians, nurses, pharmacists, and other services. These costs are best viewed as short-term investments that ultimately provide long-term cost savings because of improved clinical outcomes, with observed decreases in LOS, inpatient complications, and need for rehospitalization (148-155).

Pharmacoeconomic analyses have examined the cost-effectiveness of improved glycemic control in the hospital setting (148,149). In the Portland Diabetic Project, a 17-year prospective nonrandomized study of 4,864 patients with diabetes who underwent open heart surgical procedures, institution of continuous IV insulin therapy to achieve predetermined target BG levels reduced the incidence of deep sternal wound infections by 66%, resulting in a total net savings to the hospital of \$4,638 per patient (148). In another study, intensive glycemic control in 1,600 patients treated in a medical ICU was associated with a total cost savings of \$1,580 per patient (149). Van den Berghe et al (150) reported cost savings of \$3,476 (US dollars) per patient by strict normalization of BG levels with use of a post hoc health care resource utilization analysis of their randomized mechanically ventilated surgical ICU patients. In a retrospective analysis of patients undergoing coronary artery bypass grafting, each 50 mg/dL (2.8 mmol/L) increase in BG values on the day of and after the surgical procedure was associated with an increase in hospital cost of \$1,769 and an increase in duration of hospital stay of 0.76 day (151). In a tertiary care trauma center, implementation of a diabetes management program to reduce the monthly mean BG level by 26 mg/dL (1.4 mmol/L) (177 mg/dL to 151 mg/dL [9.8 to 8.4 mmol/L]) resulted in significant reductions in LOS (0.26 day) in association with estimated hospital savings of more than \$2 million per year (152). In another study, implementation of a subcutaneous insulin protocol for treatment of patients with hyperglycemia in the emergency department resulted in a subsequent reduction of hospital stay by 1.5 days (153).

The use of an intensified inpatient protocol by a diabetes management team resulted in correct coding and treatment of patients with previously unrecognized hyperglycemia. The LOS was reduced for both primary and secondary diagnoses of diabetes, and readmission rates declined (154). In a different study, the use of diabetes team consultation resulted in a 56% reduction in LOS and a cost reduction of \$2,353 per patient (155).

Thus, intensive glycemic control programs have reported substantial cost savings, primarily attributable to decreases in laboratory, pharmacy, and radiology costs; fewer inpatient complications; decreased ventilator days; and reductions in ICU and hospital LOS.

These reports demonstrate that optimization of inpatient glycemic management not only is effective in reducing morbidity and mortality but also is cost-effective. The business case for hospital support of glycemic management programs is based on opportunities for improving the accuracy of documentation and coding for diabetes-related

diagnoses. The case for revenue generation through billing for clinical services is based on opportunities to increase the provision of glycemic management services in the hospital. It is imperative to involve hospital administration in providing the necessary financial support for inpatient glycemic management programs that will ultimately result in cost savings in conjunction with improved patient outcomes.

**QUESTION 7: What are the optimal strategies for transition to outpatient care?**

Preparation for transition to the outpatient setting is an important goal of inpatient diabetes management and begins with the hospital admission. This entails a fundamental shift in responsibility from a situation in which hospital personnel provide the diabetes care to one in which the patient is capable of self-management. Successful coordination of this transition requires a team approach that may involve physicians, nurses, medical assistants, dietitians, case-managers, and social workers (8). Hospitals with certified diabetes educators benefit from their expertise during the discharge process.

Admission assessment obtains information regarding any prior history of diabetes or hyperglycemia, its management, and the level of glycemic control. Early assessment of a patient's cognitive abilities, literacy level, visual acuity, dexterity, cultural context, and financial resources for acquiring outpatient diabetic supplies allows sufficient time to prepare the patient and address problem areas.

Hospitalization provides a unique opportunity for addressing a patient's education in diabetes self-management (3). Because the mean hospital LOS is usually less than 5 days (2) and the capacity to learn new material may be limited during acute illness, diabetes-related education is frequently limited to an inventory of basic "survival skills."

It is recommended that the following areas be reviewed and addressed before the patient is discharged from the hospital (8):

- Level of understanding related to the diagnosis of diabetes
- Self-monitoring of BG and explanation of home BG goals
- Definition, recognition, treatment, and prevention of hyperglycemia and hypoglycemia
- Identification of health care provider who will be responsible for diabetes care after discharge
- Information on consistent eating patterns
- When and how to take BG-lowering medications, including administration of insulin (if the patient is receiving insulin for ongoing management at home)
- Sick-day management
- Proper use and disposal of needles and syringes

Medication errors and adverse drug events have been linked to poor communication of instructions to the patient at the time of discharge (156,157). This is particularly true for insulin regimens, which are inherently more complex. Because the day of discharge is not always conducive to retention of verbal instructions (158), clearly written instructions provide a reference for patients and their outpatient providers, and they provide a format for medication reconciliation between inpatient and outpatient settings. In one recent study, an insulin-specific discharge instruction form provided greater clarity and more consistent directions for insulin dosing and self-testing of BG in comparison with a generic hospital discharge form (159).

An outpatient follow-up visit with the primary care provider, endocrinologist, or diabetes educator within 1 month after discharge from the hospital is advised for all patients having hyperglycemia in the hospital (8). Clear communication with outpatient providers either directly or by means of hospital discharge summaries facilitates safe transitions to outpatient care. Providing information regarding the cause or the plan for determining the cause of hyperglycemia, related complications and comorbidities, and recommended treatments can assist outpatient providers as they assume ongoing care.

**QUESTION 8: What are areas for future research?**

The following are selected research topics and questions proposed for guiding the management of patients with hyperglycemia in various hospital settings.

**Stress Hyperglycemia**

- What are the underlying mechanisms?
- What abnormalities lead to variability in insulin resistance observed in some critically ill patients?
- What therapeutic modalities, in addition to glycemic control, would improve outcomes in critically ill patients with hyperglycemia?
- Are there optimal and safe glycemic targets specific to certain populations of critically ill patients?

**Severe Hypoglycemia**

- What is the profile of inpatients at greatest risk for severe hypoglycemia?
- What are the short-term and long-term outcomes of patients experiencing severe hypoglycemia?
- What are the true costs of inpatient hypoglycemia?

**Glycemic Targets on General Medical and Surgical Wards**

- What are optimal and safe glycemic targets in non-critically ill patients on medical and surgical wards? Recommended end points for an RCT include rates of hypoglycemia, hospital-acquired infections, other in-hospital complications, LOS, and readmission.

### Glycemic Variability

- What is the effect of glycemic variability and the rate of change in glycemia on short-term and long-term outcomes, both in ICU and non-ICU settings?

### Hospital Systems and Safety

- What hospital systems and safety measures are important for improving glycemic control and patient outcomes?
- What teams and support systems are required for safe and effective transition of patients to the outpatient setting?

### Insulin Treatment and Monitoring Instruments

- What are safe and effective strategies for inpatient use of insulin and insulin analogues?
- What is the role of continuous glucose monitoring systems in inpatient settings?

### Pediatric Inpatient Populations

- What are the optimal and safe glycemic targets in non-critically ill hospitalized children?

## SUMMARY OF RECOMMENDATIONS

### I. Critically Ill Patients

- Insulin therapy should be initiated for treatment of persistent hyperglycemia, starting at a threshold of no greater than 180 mg/dL (10.0 mmol/L).
- Once insulin therapy has been started, a glucose range of 140 to 180 mg/dL (7.8 to 10.0 mmol/L) is recommended for the majority of critically ill patients.
- Intravenous insulin infusions are the preferred method for achieving and maintaining glycemic control in critically ill patients.
- Validated insulin infusion protocols with demonstrated safety and efficacy, and with low rates of occurrence of hypoglycemia, are recommended.
- With IV insulin therapy, frequent glucose monitoring is essential to minimize the occurrence of hypoglycemia and to achieve optimal glucose control.

### II. Noncritically Ill Patients

- For the majority of noncritically ill patients treated with insulin, the premeal BG target should generally be <140 mg/dL (<7.8 mmol/L) in conjunction with random BG values <180 mg/dL (<10.0 mmol/L), provided these targets can be safely achieved.
- More stringent targets may be appropriate in stable patients with previous tight glycemic control.
- Less stringent targets may be appropriate in terminally ill patients or in patients with severe comorbidities.
- Scheduled subcutaneous administration of insulin, with basal, nutritional, and correction components, is the preferred method for achieving and maintaining glucose control.
- Prolonged therapy with SSI as the sole regimen is discouraged.
- Noninsulin antihyperglycemic agents are not appropriate in most hospitalized patients who require therapy for hyperglycemia.

- Clinical judgment and ongoing assessment of clinical status must be incorporated into day-to-day decisions regarding treatment of hyperglycemia.

### III. Safety Issues

- Overtreatment and undertreatment of hyperglycemia represent major safety concerns.
- Education of hospital personnel is essential in engaging the support of those involved in the care of inpatients with hyperglycemia.
- Caution is required in interpreting results of POC glucose meters in patients with anemia, polycythemia, hypoperfusion, or use of some medications.
- Buy-in and financial support from hospital administration are required for promoting a rational systems approach to inpatient glycemic management.

### IV. Cost

- Appropriate inpatient management of hyperglycemia is cost-effective.

### V. Discharge Planning

- Preparation for transition to the outpatient setting should begin at the time of hospital admission.
- Discharge planning, patient education, and clear communication with outpatient providers are critical for ensuring a safe and successful transition to outpatient glycemic management.

### VI. Needed Research

- A selected number of research questions and topics for guiding the management of inpatient hyperglycemia in various hospital settings are proposed.



## ACKNOWLEDGMENT

We acknowledge the medical writing assistance of Kate Mann, PharmD.

## DISCLOSURE

**Ms. Monica DiNardo** reports that she has received consultant fees from sanofi-aventis U.S. LLC.

**Dr. Daniel Einhorn** reports that he has received consultant fees from Merck & Co., Inc., consultant fees and research grant support from Amylin Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, and Takeda Pharmaceuticals North America, Inc., and research grant support from AstraZeneca 2009, GlaxoSmithKline, Johnson & Johnson Services, Inc., Eli Lilly & Company, Medtronic, Inc., and Novo Nordisk A/S and is a stockholder with Halozyme Therapeutics and MannKind Corporation.

**Dr. Richard Hellman** reports that he has no relevant conflicts of interest.

**Dr. Irl B. Hirsch** reports that he has received consultant fees from Abbott Laboratories, F. Hoffman La Roche Ltd. (Roche), Johnson & Johnson Services, Inc., and Novo Nordisk A/S.

**Dr. Silvio E. Inzucchi** reports that he has received research grant support from Eli Lilly & Company.

**Dr. Faramarz Ismail-Beigi** reports that he has no relevant conflicts of interest.

**Dr. M. Sue Kirkman** reports that she has no relevant conflicts of interest.

**Dr. Mary T. Korytkowski** reports that she has received consultant fees from Eli Lilly & Company, Merck & Co., Inc., and Novo Nordisk A/S and research grant support from sanofi-aventis U.S. LLC.

**Dr. Etie S. Moghissi** reports that she has received consultant fees from and is a stockholder with Amylin Pharmaceuticals, Inc. and Novo Nordisk A/S.

**Dr. Guillermo E. Umpierrez** reports that he has received consultant fees from Merck & Co., Inc. and consultant fees and research grant support from sanofi-aventis U.S. LLC.

## REFERENCES

1. **American Diabetes Association.** Economic costs of diabetes in the U.S. in 2007 [published correction appears in *Diabetes Care.* 2008;31:1271]. *Diabetes Care.* 2008;31:596-615.
2. **Centers for Disease Control and Prevention.** National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
3. **Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE.** Unrecognized diabetes among hospitalized patients. *Diabetes Care.* 1998;21:246-249.
4. **Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE.** Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. *J Clin Endocrinol Metab.* 2002;87:978-982.
5. **Van den Berghe G, Wouters P, Weekers F, et al.** Intensive insulin therapy in critically ill patients. *N Engl J Med.* 2001;345:1359-1367.
6. **Malmberg K, Norhammar A, Wedel H, et al.** Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction; long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. *Circulation.* 1999;99:2626-2632.
7. **Kosiborod M, Inzucchi SE, Goyal A, et al.** The relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction [abstract]. *Circulation.* 2008;118(suppl):S1109.
8. **Clement S, Braithwaite SS, Magee MF (American Diabetes Association Diabetes in Hospitals Writing Committee).** Management of diabetes and hyperglycemia in hospitals [published corrections appear in *Diabetes Care.* 2004;27:856 and *Diabetes Care.* 2004;27:1255]. *Diabetes Care.* 2004;27:553-591.
9. **Garber AJ, Moghissi ES, Bransome ED Jr, et al (American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control).** American College of Endocrinology position statement on inpatient diabetes and metabolic control. *Endocr Pract.* 2004;10:77-82.
10. **American Diabetes Association.** Standards of medical care in diabetes [published correction appears in *Diabetes Care.* 2005;28:990]. *Diabetes Care.* 2005;28(suppl 1):S4-S36.
11. **ACE/ADA Task Force on Inpatient Diabetes.** American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. *Endocr Pract.* 2006;12:458-468.
12. **Wiener RS, Wiener DC, Larson RJ.** Benefits and risks of tight glucose control in critically ill adults: a meta-analysis [published correction appears in *JAMA.* 2008;301:936]. *JAMA.* 2008;300:933-944.
13. **Brunkhorst FM, Engel C, Bloos F, et al (German Competence Network Sepsis [SepNet]).** Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med.* 2008;358:125-139.
14. **Finfer S, Chittock DR, Su SY, et al (NICE-SUGAR Study Investigators).** Intensive versus conventional glucose control in critically ill patients. *N Engl J Med.* 2009;360:1283-1297.
15. **Krinsley JS, Grover A.** Severe hypoglycemia in critically ill patients: risk factors and outcomes. *Crit Care Med.* 2007;35:2262-2267.
16. **Van den Berghe G, Wilmer A, Hermans G, et al.** Intensive insulin therapy in the medical ICU. *N Engl J Med.* 2006;354:449-461.
17. **Griesdale DE, de Souza RJ, van Dam RM, et al.** Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data [published online ahead of print March 24, 2009]. *CMAJ.* doi: 10.1503/cmaj.090206.

18. **Malmberg K (DIGAMI [Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction] Study Group).** Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ.* 1997;314:1512-1515.
19. **Furnary AP, Zerr KJ, Grunkemeier GL, Starr A.** Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures [with discussion]. *Ann Thorac Surg.* 1999;67:352-362.
20. **Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS.** The association of diabetes and glucose control with surgical site infections among cardiothoracic surgery patients. *Infect Control Hosp Epidemiol.* 2001;22:607-612.
21. **Sala J, Masiá R, González de Molina FJ, et al (REGICOR Investigators).** Short-term mortality of myocardial infarction patients with diabetes or hyperglycaemia during admission. *J Epidemiol Community Health.* 2002;56:707-712.
22. **Furnary AP, Gao G, Grunkemeier GL, et al.** Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. *J Thorac Cardiovasc Surg.* 2003;125:1007-1021.
23. **Krinsley JS.** Effect of intensive glucose management protocol on the mortality of critically ill adult patients [published correction appears in *Mayo Clin Proc.* 2005;80:1101]. *Mayo Clin Proc.* 2004;79:992-1000.
24. **Pittas AG, Siegel RD, Lau J.** Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized, controlled trials. *Arch Intern Med.* 2004;164:2005-2011.
25. **Ishihara M, Kojima S, Sakamoto T, et al (Japanese Acute Coronary Syndrome Study Investigators).** Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. *Am Heart J.* 2005;150:814-820.
26. **Mizock BA.** Alterations in carbohydrate metabolism during stress: a review of the literature. *Am J Med.* 1995;98:75-84.
27. **Devos P, Preiser JC, Mélot C (GluControl Steering Committee).** Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: final results of the GluControl study [abstract]. *Intensive Care Med.* 2007;33:S189.
28. **De La Rosa GD, Donado JH, Restrepo AH, et al (Grupo de Investigacion en Cuidado Intensivo [GICIHPTU]).** Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. *Crit Care.* 2008;12:R120.
29. **Finfer S, Delaney A.** Tight glycaemic control in critically ill adults. *JAMA.* 2008;300:963-965.
30. **Golden SH, Peart-Vigilance C, Kao WH, Brancati FL.** Perioperative glycaemic control and the risk of infectious complications in a cohort of adults with diabetes. *Diabetes Care.* 1999;22:1408-1414.
31. **Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A.** Glucose control lowers the risk of wound infection in diabetics after open heart operations. *Ann Thorac Surg.* 1997;63:356-361.
32. **Krinsley JS.** Glycemic control, diabetic status, and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycaemic management: six and one-half years experience at a university-affiliated community hospital. *Semin Thorac Cardiovasc Surg.* 2006;18:317-325.
33. **Malmberg K, Rydén L, Efendic S, et al.** Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. *J Am Coll Cardiol.* 1995;26:57-65.
34. **Malmberg K, Rydén L, Wedel H, et al (DIGAMI 2 Investigators).** Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. *Eur Heart J.* 2005;26:650-661.
35. **Cheung NW, Wong VW, McLean M.** The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study; a randomized controlled trial of insulin infusion therapy for myocardial infarction. *Diabetes Care.* 2006;29:765-770.
36. **Gandhi GY, Nuttall GA, Abel MD, et al.** Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. *Ann Intern Med.* 2007;146:233-243.
37. **Capes SE, Hunt D, Malmberg K, Gerstein HC.** Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. *Lancet.* 2000;355:773-778.
38. **Kosiborod M, Rathore SS, Inzucchi SE, et al.** Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. *Circulation.* 2005;111:3078-3086.
39. **Kosiborod M, Inzucchi SE, Krumholz HM, et al.** Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. *Circulation.* 2008;117:1018-1027.
40. **Goyal A, Mahaffey KW, Garg J, et al.** Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. *Eur Heart J.* 2006;27:1289-1297.
41. **Deedwania P, Kosiborod M, Barrett E, et al (American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism).** Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation.* 2008;117:1610-1619.
42. **Pinto DS, Skolnick AH, Kirtane AJ, et al (TIMI Study Group).** U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol.* 2005;46:178-180.
43. **Svensson AM, McGuire DK, Abrahamsson P, Dellborg M.** Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. *Eur Heart J.* 2005;26:1255-1261.
44. **Mehta SR, Yusuf S, Diaz R, et al (CREATE-ECLA Trial Group Investigators).** Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. *JAMA.* 2005;293:437-446.

#### 14 Consensus: Inpatient Hyperglycemia, *Endocr Pract.* 2009;15(No. 4)

45. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC. Relationship of early hyperglycemia to mortality in trauma patients. *J Trauma.* 2004;56:1058-1062.
46. Jeremitsky E, Omert LA, Dunham CM, Wilberger J, Rodriguez A. The impact of hyperglycemia on patients with severe brain injury. *J Trauma.* 2005;58:47-50.
47. Gale SC, Sicoutris C, Reilly PM, Schwab CW, Gracias VH. Poor glycemic control is associated with increased mortality in critically ill trauma patients. *Am Surg.* 2007;73:454-460.
48. Vogelzang M, van der Horst ICC, Nijsten MW. Hyperglycaemic index as a tool to assess glucose control: a retrospective study. *Crit Care.* 2004;8:R122- R127.
49. Duane TM, Ivatury RR, Dechert T, et al. Blood glucose levels at 24 hours after trauma fails to predict outcomes. *J Trauma.* 2008;64:1184-1187.
50. Cochran A, Davis L, Morris SE, Saffle JR. Safety and efficacy of an intensive insulin protocol in a burn-trauma intensive care unit. *J Burn Care Res.* 2008;29:187-191.
51. Wahl WL, Taddonio M, Maggio PM, Arabi S, Hemmila MR. Mean glucose values predict trauma patient mortality. *J Trauma.* 2008;65:42-47.
52. Pasternak JJ, McGregor DG, Schroeder DR, et al (IHAST Investigators). Hyperglycemia in patients undergoing cerebral aneurysm surgery: its association with long-term gross neurologic and neuropsychological function. *Mayo Clin Proc.* 2008;83:406-417.
53. Mowery NT, Gunter OL, Guillaumondegui O, et al. Stress insulin resistance is a marker for mortality in traumatic brain injury [with discussion]. *J Trauma.* 2009;66:145-153.
54. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea TM. Admission hyperglycemia is predictive of outcome in critically ill trauma patients. *J Trauma.* 2005;59:80-83.
55. Bochicchio GV, Joshi M, Bochicchio KM, et al. Early hyperglycemic control is important in critically injured trauma patients. *J Trauma.* 2007;63:1353-1358.
56. Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycemia as a prognostic indicator in trauma. *J Trauma.* 2003;55:33-38.
57. Collier B, Diaz J Jr, Forbes R, et al. The impact of a normoglycemic management protocol on clinical outcomes in the trauma intensive care unit [with discussion]. *JPEN J Parenter Enteral Nutr.* 2005;29:353-359.
58. Shin S, Britt RC, Reed SF, Collins J, Weireter LJ, Britt LD. Early glucose normalization does not improve outcome in the critically ill trauma population. *Am Surg.* 2007;73:769-772.
59. Bilotta F, Caramia R, Cernak I, et al. Intensive insulin therapy after severe traumatic brain injury: a randomized clinical trial. *Neurocrit Care.* 2008;9:159-166.
60. Davidson JA, Wilkinson A (International Expert Panel on New-Onset Diabetes After Transplantation). New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. *Diabetes Care.* 2004;27:805-812.
61. Fuji S, Kim SW, Mori S, et al. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. *Transplantation.* 2007;84:814-820.
62. Derr RL, Hsiao VC, Saudek CD. Antecedent hyperglycemia is associated with an increased risk of neutropenic infections during bone marrow transplantation. *Diabetes Care.* 2008;31:1972-1977.
63. Hammer MJ, Casper C, Gooley TA, O'Donnell PV, Boeckh M, Hirsch IB. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. *Biol Blood Marrow Transplant.* 2009;15:344-351.
64. Shim YH, Kweon TD, Lee JH, Nam SB, Kwak YL. Intravenous glucose-insulin-potassium during off-pump coronary artery bypass surgery does not reduce myocardial injury. *Acta Anaesthesiol Scand.* 2006;50:954-961.
65. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kachce S, Wilson DM. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. *Pediatrics.* 2006;118:173-179.
66. Palacio A, Smiley D, Ceron M, et al. Prevalence and clinical outcome of inpatient hyperglycemia in a community pediatric hospital. *J Hosp Med.* 2008;3:212-217.
67. Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. *J Pediatr.* 2005;146:30-34.
68. Branco RG, Garcia PC, Piva JP, Casartelli CH, Seibel V, Tasker RC. Glucose level and risk of mortality in pediatric septic shock. *Pediatr Crit Care Med.* 2005;6:470-472.
69. Tuggle DW, Kuhn MA, Jones SK, Garza JJ, Skinner S. Hyperglycemia and infections in pediatric trauma patients. *Am Surg.* 2008;74:195-198.
70. Falcao G, Ulate K, Kouzekanani K, Bielefeld MR, Morales JM, Rotta AT. Impact of postoperative hyperglycemia following surgical repair of congenital cardiac defects. *Pediatr Cardiol.* 2008;29:628-636.
71. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Early insulin therapy in very-low-birth-weight infants. *N Engl J Med.* 2008;359:1873-1884.
72. Vlasselaers D, Milants I, Desmet L, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. *Lancet.* 2009;373:547-556.
73. Pomposelli JJ, Baxter JK III, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. *JPEN J Parenter Enteral Nutr.* 1998;22:77-81.
74. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. *Stroke.* 2001;32:2426-2432.
75. Bruno A, Gregori D, Caropreso A, Lazzarato F, Petrinco M, Pagano E. Normal glucose values are associated with a lower risk of mortality in hospitalized patients. *Diabetes Care.* 2008;31:2209-2210.
76. Norhammar AM, Rydén L, Malmberg K. Admission plasma glucose: independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. *Diabetes Care.* 1999;22:1827-1831.
77. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. *JAMA.* 2003;290:2041-2047.

78. **Montori VM, Bistrian BR, McMahon MM.** Hyperglycemia in acutely ill patients. *JAMA.* 2002;288:2167-2169.
79. **Noordzij PG, Boersma E, Schreiner F, et al.** Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. *Eur J Endocrinol.* 2007;156:137-142.
80. **McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ.** The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. *Diabetes Care.* 2005;28:810-815.
81. **Baker EH, Janaway CH, Philips BJ, et al.** Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. *Thorax.* 2006;61:284-289.
82. **Egi M, Bellomo R, Stachowski E, French CJ, Hart G.** Variability of blood glucose concentration and short-term mortality in critically ill patients. *Anesthesiology.* 2006;105:244-252.
83. **Hirsch IB, Brownlee M.** Should minimal blood glucose variability become the gold standard of glycemic control? *J Diabetes Complications.* 2005;19:178-181.
84. **Inzucchi SE, Siegel MD.** Glucose control in the ICU—how tight is too tight? *N Engl J Med.* 2009;360:1346-1349.
85. **American Diabetes Association.** Standards of medical care in diabetes—2009. *Diabetes Care.* 2009;32(suppl 1):S13-S61.
86. **Rodbard HW, Blonde L, Braithwaite SS, et al (AACE Diabetes Mellitus Clinical Practice Guidelines Task Force).** American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus [published correction appears in *Endocr Pract.* 2008;14:802-803]. *Endocr Pract.* 2007;13(suppl 1):1-68.
87. **Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB.** A new look at screening and diagnosing diabetes mellitus. *J Clin Endocrinol Metab.* 2008;93:2447-2453.
88. **Cryer PE, Davis SN, Shamooh H.** Hypoglycemia in diabetes. *Diabetes Care.* 2003;26:1902-1912.
89. **Mitrakou A, Ryan C, Veneman T, et al.** Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. *Am J Physiol.* 1991;260(1, pt 1):E67-E74.
90. **Korytkowski MT, DiNardo M, Donihi AC, Bigi L, DeVita M.** Evolution of a diabetes inpatient safety committee. *Endocr Pract.* 2006;12(suppl 3):91-99.
91. **DiNardo MM, Noschese M, Korytkowski MT, Freeman S.** The medical emergency team and rapid response system: finding, treating, and preventing hypoglycemia. *Jt Comm J Qual Patient Saf.* 2006;32:591-595.
92. **DiNardo M, Donihi AC, DeVita M, Siminerio L, Rao H, Korytkowski MT.** A nurse directed protocol for recognition and treatment of hypoglycemia in hospitalized patients. *Pract Diabetol.* 2005;22:37-40.
93. **Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA.** Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. *Endocr Pract.* 2006;12:358-362.
94. **Curll M, DiNardo M, Noschese M, Korytkowski MT.** Menu selection, glycaemic control, and satisfaction with standard and patient-controlled consistent carbohydrate meal plans in hospitalized patients with diabetes. *Qual Saf Health Care.* 2009. In press.
95. **Goldberg PA, Bozzo JE, Thomas PG, et al.** “Glucometrics”—assessing the quality of inpatient glucose management. *Diabetes Technol Ther.* 2006;8:560-569.
96. **Donihi A, Rea R, Mihalko M, Korytkowski M.** Comparison of different methods of transitioning MICU patients from intravenous to subcutaneous insulin [abstract]. *Diabetes.* 2007;57:A542.
97. **Moghissi ES.** Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes. *Mt Sinai J Med.* 2008;75:558-566.
98. **Goldberg PA, Siegel MD, Sherwin RS, et al.** Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. *Diabetes Care.* 2004;27:461-467.
99. **Rea RS, Donihi AC, Bobeck M, et al.** Implementing an intravenous insulin infusion protocol in the intensive care unit. *Am J Health Syst Pharm.* 2007;64:385-395.
100. **Nazer LH, Chow SL, Moghissi ES.** Insulin infusion protocols for critically ill patients: a highlight of differences and similarities. *Endocr Pract.* 2007;13:137-146.
101. **DeSantis AJ, Schmeltz LR, Schmidt K, et al.** Inpatient management of hyperglycemia: the Northwestern experience. *Endocr Pract.* 2006;12:491-505.
102. **Noschese M, Donihi AC, Koerbel G, et al.** Effect of a diabetes order set on glycaemic management and control in the hospital. *Qual Saf Health Care.* 2008;17:464-468.
103. **Noschese M, Donihi A, Ruppert K, et al.** A guideline for diabetes self management in the hospital: experience with 50 patients using continuous insulin infusions. Paper presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-26, 2007; Chicago, IL.
104. **Umpierrez GE, Hor T, Smiley D, et al.** Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine Hagedorn plus regular in medical patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2009;94:564-569.
105. **Moghissi ES, Hirsch IB.** Hospital management of diabetes. *Endocrinol Metab Clin North Am.* 2005;34:99-116.
106. **Umpierrez GE, Smiley D, Zisman A, et al.** Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). *Diabetes Care.* 2007;30:2181-2186.
107. **Umpierrez GE, Palacio A, Smiley D.** Sliding scale insulin use: myth or insanity? *Am J Med.* 2007;120:563-567.
108. **Queale WS, Seidler AJ, Brancati FL.** Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. *Arch Intern Med.* 1997;157:545-552.
109. **Korytkowski MT, Salata RJ, Koerbel GL, et al.** Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. *Diabetes Care.* 2009;32:594-596.
110. **Schnipper JL, Barsky EE, Shaykevich S, Fitzmaurice G, Pendergrass ML.** Inpatient management of diabetes and hyperglycemia among general medicine patients at a large teaching hospital. *J Hosp Med.* 2006;1:145-150.

16 Consensus: Inpatient Hyperglycemia, *Endocr Pract.* 2009;15(No. 4)

111. **Hirsch IB.** Sliding scale insulin—time to stop sliding. *JAMA.* 2009;301:213-214.
112. **Umpierrez GE.** Basal versus sliding-scale regular insulin in hospitalized patients with hyperglycemia during enteral nutrition therapy. *Diabetes Care.* 2009;32:751-753.
113. **Donihi AC, Yang E, Mark SM, Sirio CA, Weber RJ.** Scheduling of pharmacist-provided medication education for hospitalized patients. *Hosp Pharm.* 2008;43:121-126.
114. **Cook CB, Boyle ME, Cisar NS, et al.** Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital setting: proposed guidelines and outcomes measures [published correction appears in *Diabetes Educ.* 2006;32:130]. *Diabetes Educ.* 2005;31:849-857.
115. **Bailon RM, Partlow BJ, Miller-Cage V, et al.** Continuous subcutaneous insulin infusion (insulin pump) therapy can be safely used in the hospital in select patients. *Endocr Pract.* 2009;15:24-29.
116. **Pancorbo-Hidalgo PL, García-Fernandez FP, Ramírez-Pérez C.** Complications associated with enteral nutrition by nasogastric tube in an internal medicine unit. *J Clin Nurs.* 2001;10:482-490.
117. **Arinzon Z, Shabat S, Shuval I, Peisakh A, Berner Y.** Prevalence of diabetes mellitus in elderly patients received enteral nutrition long-term care service. *Arch Gerontol Geriatr.* 2008;47:383-393.
118. **Nylen ES, Muller B.** Endocrine changes in critical illness. *J Intensive Care Med.* 2004;19:67-82.
119. **Reider J, Lin H, Dinardo M, Donihi A, Saul M, Korytkowski M.** Efficacy of a guideline for treatment of corticosteroid related hyperglycemia in the hospital [abstract]. *Diabetes.* 2008;57:A574.
120. **Hellman R.** A systems approach to reducing errors in insulin therapy in the inpatient setting. *Endocr Pract.* 2004;10(suppl 2):100-108.
121. **Hellman R.** Patient safety and inpatient glycemic control: translating concepts into action. *Endocr Pract.* 2006;12(suppl 3):49-55.
122. **Cryer PE.** Hypoglycaemia: the limiting factor in the glycaemic management of the critically ill? *Diabetologia.* 2006;49:1722-1725.
123. **Cook CB, Castro JC, Schmidt RE, et al.** Diabetes care in hospitalized noncritically ill patients: more evidence for clinical inertia and negative therapeutic momentum. *J Hosp Med.* 2007;2:203-211.
124. **Braithwaite SS, Buie MM, Thompson CL, et al.** Hospital hypoglycemia: not only treatment but also prevention. *Endocr Pract.* 2004;10(suppl 2):89-99.
125. **Knecht LA, Gauthier SM, Castro JC, et al.** Diabetes care in the hospital: is there clinical inertia? *J Hosp Med.* 2006;1:151-160.
126. **Flansbaum B.** Management of hyperglycemia. *J Hosp Med.* 2006;1:382-385.
127. **Cook CB, Jameson KA, Hartsell ZC, et al.** Beliefs about hospital diabetes and perceived barriers to glucose management among inpatient midlevel practitioners. *Diabetes Educ.* 2008;34:75-83.
128. **Smith WD, Winterstein AG, Johns T, Rosenberg E, Sauer BC.** Causes of hyperglycemia and hypoglycemia in adult inpatients. *Am J Health Syst Pharm.* 2005;62:714-719.
129. **Seley J, Wallace M.** Meeting the challenge of inpatient diabetes education: an interdisciplinary approach. In: Weinger K, Carver C, eds. *Educating Your Patient With Diabetes.* Totowa, New Jersey: Humana Press, 2009: 81-96. <http://www.springerlink.com/content/m646r4121x476x45/>. Accessed for verification April 7, 2009.
130. **van der Crabben SN, Blümer RM, Stegenga ME, et al.** Early endotoxemia increases peripheral and hepatic insulin sensitivity in healthy humans. *J Clin Endocrinol Metab.* 2009;94:463-468.
131. **Taylor BE, Schallom ME, Sona CS, et al.** Efficacy and safety of an insulin infusion protocol in a surgical ICU. *J Am Coll Surg.* 2006;202:1-9.
132. **Cryer PE.** Diverse causes of hypoglycemia-associated autonomic failure in diabetes. *N Engl J Med.* 2004;350:2272-2279.
133. **Rubin DJ, Moshang J, Jabbour SA.** Diabetes knowledge: are resident physicians and nurses adequately prepared to manage diabetes? *Endocr Pract.* 2007;13:17-21.
134. **Lansang MC, Harrell H.** Knowledge on inpatient diabetes among fourth-year medical students. *Diabetes Care.* 2007;30:1088-1091.
135. **Baldwin D, Villanueva G, McNutt R, Bhatnagar S.** Eliminating inpatient sliding-scale insulin: a reeducation project with medical house staff. *Diabetes Care.* 2005;28:1008-1011.
136. **Cohen MR, Proulx SM, Crawford SY.** Survey of hospital systems and common serious medication errors. *J Healthc Risk Manag.* 1998;18:16-27.
137. **Amori RE, Pittas AG, Siegel RD, et al.** Inpatient medical errors involving glucose-lowering medications and their impact on patients: review of 2,598 incidents from a voluntary electronic error-reporting database. *Endocr Pract.* 2008;14:535-542.
138. **Scott MG, Bruns DE, Boyd JC, Sacks DB.** Tight glucose control in the intensive care unit: are glucose meters up to the task? *Clin Chem.* 2009;55:18-20.
139. **D’Orazio P, Burnett RW, Fogh-Andersen N, et al (International Federation of Clinical Chemistry Scientific Division Working Group on Selective Electrodes and Point of Care Testing).** Approved IFCC recommendation on reporting results for blood glucose (abbreviated). *Clin Chem.* 2005;51:1573-1576.
140. **Dungan K, Chapman J, Braithwaite SS, Buse J.** Glucose measurement: confounding issues in setting targets for inpatient management. *Diabetes Care.* 2007;30:403-409.
141. **Boyd JC, Bruns DE.** Quality specifications for glucose meters: assessment simulation modeling of errors in insulin dose. *Clin Chem.* 2001;47:209-214.
142. **Goldberg PA, Siegel MD, Russell RR, et al.** Experience with the continuous glucose monitoring system in a medical intensive care unit. *Diabetes Technol Ther.* 2004;6:339-347.
143. **Murakami A, Gutierrez MA, Lage SH, Rebelo MF, Guiraldelli RH, Ramires JA.** A continuous glucose monitoring system in critical cardiac patients in the intensive care unit. *Comput Cardiol.* 2006;17-20:233-236.



144. **Page A, ed. (Committee on the Work Environment for Nurses and Patient Safety, Board on Health Care Services, Institute of Medicine of the National Academies).** *Keeping Patients Safe: Transforming the Work Environment of Nurses.* Washington, DC: National Academies Press, 2004.
145. **Bates D, Clark NG, Cook RI, et al (Writing Committee on Patient Safety and Medical System Errors in Diabetes and Endocrinology).** American College of Endocrinology and American Association of Clinical Endocrinologists position statement on patient safety and medical system errors in diabetes and endocrinology. *Endocr Pract.* 2005;11:197-202.
146. **Bates DW, Leape LL, Cullen DJ, et al.** Effect of computerized physician order entry and a team intervention on prevention of serious medical errors. *JAMA.* 1998;280:1311-1316.
147. **Bates DW, Gawande AA.** Improving patient safety with information technology. *N Engl J Med.* 2003;348:2526-2534.
148. **Furnary AP, Wu Y, Bookin SO.** Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. *Endocr Pract.* 2004;10(suppl 2):21-33.
149. **Krinsley JS, Jones RL.** Cost analysis of intensive glycemic control in critically ill adult patients. *Chest.* 2006;129:644-650.
150. **Van den Berghe G, Wouters PJ, Kesteloot K, Hilleman DE.** Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. *Crit Care Med.* 2006;34:612-616.
151. **Estrada CA, Young JA, Nifong LW, Chitwood WR Jr.** Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. *Ann Thorac Surg.* 2003;75:1392-1399.
152. **Newton CA, Young S.** Financial implications of glycemic control: results of an inpatient diabetes management program. *Endocr Pract.* 2006;12(suppl 3):43-48.
153. **Munoz C, Villanueva G, Fogg L, et al.** Impact of a subcutaneous insulin protocol in the emergency department: Rush Emergency Department Hyperglycemia Intervention (REDHI) [published online ahead of print September 29, 2008]. *J Emerg Med.* 2008.
154. **Olson L, Muchmore J, Lawrence CB.** The benefits of inpatient diabetes care: improving quality of care and the bottom line. *Endocr Pract.* 2006;12(suppl 3):35-42.
155. **Levetan CS, Salas JR, Wilets IF, Zumoff B.** Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. *Am J Med.* 1995;99:22-28.
156. **Kripalani S, Jackson AT, Schnipper JL, Coleman EA.** Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists. *J Hosp Med.* 2007;2:314-323.
157. **Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW.** The incidence and severity of adverse events affecting patients after discharge from the hospital. *Ann Intern Med.* 2003;138:161-167.
158. **Large BE.** Providing timely discharge counseling. *Am J Health Syst Pharm.* 1999;56:1074-1077.
159. **Lauster CD, Gibson JM, DiNella JV, DiNardo M, Korytkowski MT.** Implementation of standardized instructions for insulin at hospital discharge. *J Hosp Med.* In press.